Brown, Lisle/Cummings’s Novavax NVAX Stock Holding History

Brown, Lisle/Cummings’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-90	Closed	-$780	–	760
2025 Q3	$780	Hold	90	–	–	﹤0.01%	720
2025 Q2	$567	Hold	90	–	–	﹤0.01%	745
2025 Q1	$577	Hold	90	–	–	﹤0.01%	745
2024 Q4	$724	Hold	90	–	–	﹤0.01%	633
2024 Q3	$1.14K	Hold	90	–	–	﹤0.01%	594
2024 Q2	$1.14K	Hold	90	–	–	﹤0.01%	582
2024 Q1	$430	Hold	90	–	–	﹤0.01%	550
2023 Q4	$432	Hold	90	–	–	﹤0.01%	562
2023 Q3	$652	Hold	90	–	–	﹤0.01%	541
2023 Q2	$669	Hold	90	–	–	﹤0.01%	546
2023 Q1	$624	Hold	90	–	–	﹤0.01%	524
2022 Q4	$925	Hold	90	–	–	﹤0.01%	505
2022 Q3	$1.64K	Hold	90	–	–	﹤0.01%	477
2022 Q2	$4.63K	Hold	90	–	–	﹤0.01%	422
2022 Q1	$6.63K	Hold	90	–	–	﹤0.01%	422
2021 Q4	$12.9K	Buy	+90	New	+$15.5K	0.01%	365

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown, Lisle/Cummings's NVAX Position: Q4 2025 in Review

Brown, Lisle/Cummings sold out of Novavax (NVAX) in Q4 2025, closing a stake of 90 shares — an estimated $780 sold.

Brown, Lisle/Cummings first reported a position in NVAX in Q4 2021 and held it in 16 quarters. The position peaked at $12.9K in Q4 2021. 235 funds tracked by Wall St. Rank hold NVAX as of Q4 2025.

Brown, Lisle/Cummings reported no remaining Novavax position as of Q4 2025 after selling out during the quarter.
Brown, Lisle/Cummings sold 90 Novavax shares in Q4 2025, an estimated $780.
Brown, Lisle/Cummings first reported a position in Novavax in Q4 2021 and held it in 16 quarters.
Brown, Lisle/Cummings's Novavax position peaked at $12.9K in Q4 2021.
235 funds tracked by Wall St. Rank held Novavax as of Q4 2025.

Based on Brown, Lisle/Cummings's 13F filing for Q4 2025, filed 23 Jan 2026.